Effectiveness of lurasidone for patients with schizophrenia following 6 weeks of acute treatment with lurasidone, olanzapine, or placebo: A 6-month, open-label, extension study

Journal of Clinical Psychiatry

Volumn 74, Issue 5, 2013, Pages 507-515

  Stahl, Stephen M ^a   Cucchiaro, Josephine ^b   Simonelli, Doreen ^b   Hsu, Jay ^b   Pikalov, Andrei ^b   Loebel, Antony ^b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b DAINIPPON SUMITOMO PHARMA CO LTD   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

LURASIDONE; OLANZAPINE; PLACEBO;

ACUTE PSYCHOSIS; ADULT; AKATHISIA; ANXIETY; ARTICLE; BODY MASS; BODY TEMPERATURE; CHOLESTEROL BLOOD LEVEL; CLINICAL GLOBAL IMPRESSION SCALE; CLINICAL TRIAL; DIASTOLIC BLOOD PRESSURE; DRUG EFFICACY; DRUG INDUCED HEADACHE; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; DYSTONIA; ELECTROCARDIOGRAM; EXTRAPYRAMIDAL SYMPTOM; FEMALE; HEART RATE; HUMAN; INSOMNIA; LONG TERM CARE; MAJOR CLINICAL STUDY; MALE; MENTAL DISEASE; MORNING DOSAGE; MULTICENTER STUDY; NAUSEA; NEUROLOGIC DISEASE; OPEN STUDY; PARKINSONISM; PATIENT COMPLIANCE; POSITIVE AND NEGATIVE SYNDROME SCALE; PRIORITY JOURNAL; PSYCHOSIS; QT INTERVAL; RESTLESSNESS; SCHIZOPHRENIA; SIDE EFFECT; SOMNOLENCE; SUICIDAL IDEATION; SUICIDE ATTEMPT; SYSTOLIC BLOOD PRESSURE; TORTICOLLIS; TREMOR; VOMITING; WAIST CIRCUMFERENCE; WEIGHT GAIN; WEIGHT REDUCTION;

EID: 84878245007     PISSN: 01606689     EISSN: None     Source Type: Journal    
DOI: 10.4088/JCP.12m08084     Document Type: Article

References (34)

1. Ishibashi T, Horisawa T, Tokuda K, et al. Pharmacological profile of lurasidone, a novel antipsychotic agent with potent 5-hydroxytryptamine 7 (5-HT7) and 5-HT1A receptor activity. J Pharmacol Exp Ther. 2010;334(1):171-181. doi:10.124/jpet.10.167346 PubMed
2. Nakamura M, Ogasa M, Guarino J, et al. Lurasidone in the treatment of acute schizophrenia: a double-blind, placebo-controlled trial. J Clin Psychiatry. 2009;70(6):829-836. doi:10.408/JCP.08m04905 PubMed
3. Potkin SG, Ogasa M, Cucchiaro J, et al. Double-blind comparison of the safety and efficacy of lurasidone and ziprasidone in clinically stable outpatients with schizophrenia or schizoaffective disorder. Schizophr Res. 2011;132(2-3):101-107. doi:10.1016/j.schres.201.04.08 PubMed
4. Meltzer HY, Cucchiaro J, Silva R, et al. Lurasidone in the treatment of schizophrenia: a randomized, double-blind, placebo- and olanzapine-controlled study. Am J Psychiatry. 2011;168(9):957-967. doi:10.176/api.ajp.201.1060907 PubMed
5. Loebel A, Cucchiaro J, Silva R, et al. Efficacy of lurasidone in schizophrenia: results of a pooled analysis based on a 5-factor model of schizophrenia. Schizophr Res. 2010;117(2-3):267. doi:10.1016/j.schres.2010.02. 425
6. Citrome L. Lurasidone for schizophrenia: a review of the efficacy and safety profile for this newly approved second-generation antipsychotic. Int J Clin Pract. 2011;65(2):189-210. doi:10.1/j.1742-1241.2010.02587.x PubMed
7. Reynolds GP, Kirk SL. Metabolic side effects of antipsychotic drug treatment-pharmacological mechanisms. Pharmacol Ther. 2010;125(1):169-179. doi:10.1016/j.pharmthera.209.10.010 PubMed
8. Stahl SM, Mignon L, Meyer JM. Which comes first: atypical antipsychotic treatment or cardiometabolic risk? Acta Psychiatr Scand. 2009;119(3):171-179. doi:10.1/j.160-047.208.0134.x PubMed
9. Newcomer JW. Second-generation (atypical) antipsychotics and metabolic effects: a comprehensive literature review. CNS Drugs. 2005;19(suppl 1):1-93. doi:10.2165/023210-2051901-01 PubMed (Pubitemid 40677047)
10. Pikalov A, Cucchiaro J, Ogasa M, et al. Effect of lurasidone on weight and metabolic parameters: results from pooled short-term placebo-controlled and long-term trials in schizophrenia [abstract no. NR06-49]. Presented at: 164th Annual Meeting of the American Psychiatric Association; May 14-18, 2011; Honolulu, HI.
11. Citrome L, Cucchiaro J, Sarma K, et al. Long-term safety and tolerability of lurasidone in schizophrenia: a 12-month, double-blind, active-controlled study. Int Clin Psychopharmacol. 2012;27(3):165-176. doi:10.1097/YIC. 0b013e32835281ef PubMed
12. International Conference on Harmonisation (ICH). ICH Harmonised Tripartite Guideline: Guideline for Good Clinical Practice. http://www.ich.org/ fileadmin/Public-Web-Site/ICH-Products/Guidelines/Efficacy/E6-R1/Step4/ E6-R1--Guideline.pdf. Updated June 1996. Accessed January 17, 2012.
13. Simpson GM, Angus JWS. A rating scale for extrapyramidal side effects. Acta Psychiatr Scand suppl. 1970;212(S212):11-19. doi:10.1/j.160-047.1970. tb0206.x PubMed
14. Barnes TR. A rating scale for drug-induced akathisia. Br J Psychiatry. 1989;154(5):672-676. doi:10.192/bjp.154.5.672 PubMed (Pubitemid 19154942)
15. Guy W, ed. ECDEU Assessment Manual for Psychopharmacology. US Department of Health, Education and Welfare publication (ADM) 76-338. Rockville, MD: National Institute of Mental Health; 1976.
16. Kay SR, Fiszbein A, Opler LA. The Positive and Negative Syndrome Scale (PANSS) for schizophrenia. Schizophr Bull. 1987;13(2):261-276. doi:10.1093/schbul/13.2.261 PubMed (Pubitemid 18039085)
17. Sajatovic M, Velligan DI, Weiden PJ, et al. Measurement of psychiatric treatment adherence. J Psychosom Res. 2010;69(6):591-599. doi:10.1016/j. jpsychores.209.05.07 PubMed
18. McEvoy JP, Citrome L, Hernandez D, et al. Effectiveness of lurasidone in patients with schizophrenia or schizoaffective disorder switched from other antipsychotics: a randomized, 6-week, open-label study. J Clin Psychiatry. 2013;74(2):170-179. 10.4088/JCP.12m07992.
19. Ogasa M, Kimura T, Nakamura M, et al. Lurasidone in the treatment of schizophrenia: a 6-week, placebo-controlled study. Psychopharmacology (Berl). 2013;225(3):519-530. doi:10.107/s0213-012-2838-2 PubMed
20. Loebel A, Cucchiaro J, Sarma K, et al. Efficacy and safety of lurasidone 80mg/day and 160mg/day in the treatment of schizophrenia: a randomized, double-blind, placebo- and active-controlled trial [published online ahead of print February 13, 2013]. Schizophr Res. doi:10.1016/j.schres.2013.01.09 PubMed
21. Kane JM, Fleischhacker WW, Hansen L, et al. Akathisia: an updated review focusing on second-generation antipsychotics. J Clin Psychiatry. 2009;70(5):627-643. doi:10.408/JCP.08r04210 PubMed
22. Masand PS. A review of pharmacologic strategies for switching to atypical antipsychotics. Prim Care Companion J Clin Psychiatry. 2005;7(3):121-129. doi:10.408/PC.v07n0309 PubMed (Pubitemid 41783228)
23. Casey DE, Carson WH, Saha AR, et al Aripiprazole Study Group. Switching patients to aripiprazole from other antipsychotic agents: a multicenter randomized study. Psychopharmacology (Berl). 2003;166(4):391-399. doi:10.107/s0213-02-134-3 PubMed (Pubitemid 36469941)
24. Newcomer JW, Campos JA, Marcus RN, et al. A multicenter, randomized, double-blind study of the effects of aripiprazole in overweight subjects with schizophrenia or schizoaffective disorder switched from olanzapine. J Clin Psychiatry. 2008;69(7):1046-1056. doi:10.408/JCP.v69n0702 PubMed (Pubitemid 352031586)
25. Stroup TS, McEvoy JP, Ring KD, et al Schizophrenia Trials Network. A randomized trial examining the effectiveness of switching from olanzapine, quetiapine, or risperidone to aripiprazole to reduce metabolic risk: Comparison of Antipsychotics for Metabolic Problems (CAMP). Am J Psychiatry. 2011;168(9):947-956. doi:10.176/api.ajp.201.101609 PubMed
26. Weiden PJ, Daniel DG, Simpson G, et al. Improvement in indices of health status in outpatients with schizophrenia switched to ziprasidone. J Clin Psychopharmacol. 2003;23(6):595-600. doi:10.1097/01.jcp.095347.32154.08 PubMed (Pubitemid 37443191)
27. Weiden PJ, Newcomer JW, Loebel AD, et al. Long-term changes in weight and plasma lipids during maintenance treatment with ziprasidone. Neuropsychopharmacology. 2008;33(5):985-994. doi:10.1038/sj.np.1301482 PubMed (Pubitemid 351367540)
28. Weiden PJ, Simpson GM, Potkin SG, et al. Effectiveness of switching to ziprasidone for stable but symptomatic outpatients with schizophrenia. J Clin Psychiatry. 2003;64(5):580-588. doi:10.408/JCP.v64n0514 PubMed (Pubitemid 36618289)
29. De Hert M, Yu W, Detraux J, et al. Body weight and metabolic adverse effects of asenapine, iloperidone, lurasidone and paliperidone in the treatment of schizophrenia and bipolar disorder: a systematic review and exploratory meta-analysis. CNS Drugs. 2012;26(9):733-759. doi:10.2165/163450-0-0 PubMed
30. Rettenbacher MA, Hofer A, Ebenbichler C, et al. Prolactin levels and sexual adverse effects in patients with schizophrenia during antipsychotic treatment. J Clin Psychopharmacol. 2010;30(6):711-715. doi:10.1097/JCP. 0b013e3181faf0e3 PubMed
31. Lu ML, Shen WW, Chen CH. Time course of the changes in antipsychotic-induced hyperprolactinemia following the switch to aripiprazole. Prog Neuropsychopharmacol Biol Psychiatry. 2008;32(8):1978-1981. doi:10.1016/j.pnpbp.208.09.016 PubMed
32. Melkersson K, Berinder K, Hulting AL. Effect of antipsychotic-induced hyperprolactinemia on anthropometric measures, insulin sensitivity and lipid profile in patients with schizophrenia or related psychoses. Neuroendocrinol Lett. 2011;32(4):428-436. PubMed
33. Liu-Seifert H, Adams DH, Kinon BJ. Discontinuation of treatment of schizophrenic patients is driven by poor symptom response: a pooled post-hoc analysis of four atypical antipsychotic drugs. BMC Med. 2005;3(1):21. doi:10.186/1741-7015-3-21 PubMed
34. Mullins CD, Obeidat NA, Cuffel BJ, et al. Risk of discontinuation of atypical antipsychotic agents in the treatment of schizophrenia. Schizophr Res. 2008;98(1-3):8-15. doi:10.1016/j.schres.207.04.035 PubMed (Pubitemid 350245583)